Adaptive Biotechnologies eyes ‘strategic alternatives’ for its 2 businesses


Seattle-based Adaptive Biotechnologies has hired Goldman Sachs to explore alternatives for its two businesses. "All options are on the table right now," CEO Chad Robins said.

Previous Augment Therapy adds $1.7 million for AR exercise technology
Next Downtown Los Angeles primed for residential growth with 26,000 units in pipeline, report finds